Background
==========

The methods of analysis of the colon cancer transcriptome described thus far produce large quantities of data in their output ([@b1-tog-2-2007-001]; [@b22-tog-2-2007-001]). Given the often arbitrary nature of the statistical thresholds for determining disease association, the functional relevance of many "over-expressed" genes is often unclear ([@b13-tog-2-2007-001]; [@b29-tog-2-2007-001]). The absence of hypothesis in many microarray papers has yielded as many questions as answers ([@b24-tog-2-2007-001]).

One approach to this "data overload" is to focus on specific biological processes rather than individual genes that are altered in malignant cells. Such processes are driven by transcription factors that are common to genes which share similar functional contexts e.g. proliferation, invasion ([@b20-tog-2-2007-001]; [@b31-tog-2-2007-001]). The promoter regions of these genes contain patterns of transcription factor binding sites (promoter modules) that form the basis for such co-regulation. These modules contain at least two transcription factor binding sites separated by a defined distance ([@b8-tog-2-2007-001]). By identifying the promoter modules prevalent in genes that are known to share a common biological function, one can use these as a starting point to detect previously unknown genes that are involved in this process ([@b31-tog-2-2007-001]). The presence of these modules in a genes' promoter region can positively or negatively influence functional processes. In this manner, a network of co-regulated genes can be determined that are implicated in specific processes ([@b16-tog-2-2007-001]). This approach has been used successfully in detecting interferon-responsive genes in inflammation, and novel cell-junction associated proteins ([@b4-tog-2-2007-001]; [@b12-tog-2-2007-001]).

The purpose of this study was to use bioinformatic techniques to determine promoter modules common to those genes in the colon cancer transcriptome that are involved in cell proliferation. In this paper we utilize an integrated bioinformatics pathway to identify novel genes associated with cell proliferation in colon cancer, and validate this approach in an *in vitro* model.

Methods
=======

Bioinformatic techniques
------------------------

An outline of the bioinformatics pipeline is illustrated in [Figure 1](#f1-tog-2-2007-001){ref-type="fig"}. A transcriptional profile of colorectal cancer was produced by comparing cDNA libraries obtained from normal colon and colon carcinoma with Digital Differential Display (DDD), as previously described ([@b18-tog-2-2007-001]). Briefly, the relative abundance of ESTs in colon cancer libraries was compared to normal tissue libraries, and those genes significantly over-expressed in colon cancer were extracted. The output was ontologically classified using *Onto-Express* to select those transcripts associated with cell proliferation ([@b11-tog-2-2007-001]). The accession numbers of these transcripts were uploaded to *Gene2Promoter* (Genomatix Software GmbH), a software program that allowed identification of promoter regions based on the individual transcripts in a gene expression profile ([@b31-tog-2-2007-001]). The promoter sequences from *Gene2Promoter* were submitted to *Frame-Worker*, ([@b9-tog-2-2007-001]) and once a model common to the input promoters was identified, its presence was screened for in known promoters of the human genome using *Model Inspector* ([@b17-tog-2-2007-001]). Briefly, all matches for individual elements of the module which score above a pre-set threshold are located in the promoter database. These individual elements are combined to match the organization (element order and distances) of the input module, to evaluate the fit of the model. Finally, *Bibliosphere* was utilized to examine the characteristics of selected genes based on the published literature ([@b23-tog-2-2007-001]).

Gene expression
---------------

Public gene expression repositories derived from microarray data from normal colon, colonic cancers and colon cancer cell lines, were interrogated for genes of interest. The normal colon microarray profile originated from pooled samples from normal colonic tissue (*Gene Expression Omnibus* tissue GSM44680) hybridized to the Affymetrix GeneChip Human Genome U133 Array ([@b10-tog-2-2007-001]). The results are expressed in log2 of user-provided counts for comparison to other normal tissues. Colon cancer tissue expression profile was obtained from the transcriptome of 10 colorectal adenocarcinomas hybridized to the U95a Affymetrix GeneChip and compared to other human cancers ([@b26-tog-2-2007-001]). Finally, the microarray data from a primary colon cancer (SW480) and a metastatic colon cancer cell line (SW620) hybridized to the Affymetrix GeneChip Human Genome U133 Array was surveyed ([@b19-tog-2-2007-001]). The results are expressed in log2 of user-provided counts for comparison between the cell lines.

Cell lines
----------

The Caco~2~ human colonocyte cell line was purchased form ATCC (LGC Promochem, U.K.) and the T84 cells were a kind gift from Dr. Cormac Taylor, UCD. Cell lines were cultured in minimum essential medium (Caco~2~) or mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium under standard conditions (T84).

siRNA transfection
------------------

Prior to transfection 1×10^5^ cells were seeded in 500 μl of medium in each well of a 24 well plate and cultured until 50--80% confluent (∼24 hours). For transfection, 0.5 μg of custom-designed siRNA (Dharmacon, IL, U.S.A.) was diluted in 100 μl medium and 1.5 μl RNAifect transfection reagent added (Qiagen, U.K.) at a 1:3 ratio and added to each well as per protocol. Three controls were used for each experiment; a positive control of laminin siRNA for mRNA quantification, a positive control of fluorescent-labeled siRNA for microscopy, and negative controls of medium only, transfection reagent only and scrambled siRNA only. The transfected cells were incubated for 24 hours under normal conditions.

RT-PCR
------

RNA extraction was subsequently performed from cells using the RNeasy kit (Qiagen, U.K.), and reverse transcribed using SuperScript II (Promega, U.K.). Quantitative PCR was performed using an ABIPrism Taqman PCR machine. Expression levels of individual genes were normalized to 18s RNA.

Cell proliferation assay
------------------------

In order to determine the effect of siRNA on cell proliferation rates, transfected CaCO~2~ cells were seeded into 96-well plates at a concentration of 1×10^4^ cells in 100 μl per well and allowed to adhere overnight. The MTS cell proliferation assay (Promega, U.K.) was used to assess proliferation rates at 48 hours, based on absorbance at 490 nm in an ELISA plate reader. Proliferation ratios were based on comparison of mean absorbance values for transfected and untransfected wells using one-way ANOVA.

Statistical analysis
--------------------

Statistical analysis of laboratory results was performed using StatView software (SAS Institute, Cary, NC). Normalised gene expression was analysed using ANOVA, after testing for equality of variance. A p \< 0.05 was considered significant. The differential expression profiles, promoter analysis and module detection all contain integral statistical thresholds for results as described in the results section.

Results
=======

An EGRF/ETSF transcription factor module is prevalent in cell proliferation-associated genes over-expressed in colorectal cancer
--------------------------------------------------------------------------------------------------------------------------------

Digital Differential Display comparison of normal colon to colorectal cancer cDNA libraries identified 163 transcripts differentially expressed in colon cancer, of which 16 were classified as involved in cellular proliferation ([supplementary 1](#SD1){ref-type="supplementary-material"})([@b18-tog-2-2007-001]). These 16 genes were the source material for promoter screening. The loci of these 16 genes were entered into *Gene2Promoter*, which detected 30 unique promoters assigned to 30 transcripts in the mapped regions; all transcripts with at least one exon identical to one of the mapped exons and their promoters were listed ([Table 1](#t1-tog-2-2007-001){ref-type="table"}). Fifteen of these promoters had been experimentally verified, and the other 15 were computational predictions based in sequence location and content.

The identified promoter sequences were investigated using *FrameWorker* software, which detects patterns in transcription factor binding sites (TFBS). We searched for modules containing at least 2 elements (TFBS), at a distance of 5--50 nucleotides apart, and adjusted the quorum constraint (prevalence threshold) until the program identified a common module. No individual module was common to all the input promoter sequences. However, one complex module, containing members of the EGRF and ETSF transcription factor binding site families, was present in 18/30 (60%) of the input promoters ([Fig. 2](#f2-tog-2-2007-001){ref-type="fig"}). The specificity score of this model had a *p*-value of 0.0059 e.g. the probability that an equal or greater number of sequences with a model match would be obtained in a randomly drawn sample of the same size as the input sequence set. The relative occurrence of individual model matches in a background promoter sequence set of 5000 human promoters scanned with this module was 0.27 and 0.50 for EGRF and ETSF respectively.

This EGRF/ETSF module contains members of the Early Growth Response Factor family and the ETS factor family at a distance of 6--44 base pairs between elements. The matrices (transcription factors) of the EGRF family were EGR1, EGR2, EGR3, EGR4 and Wilms tumour suppressor. The re-value, an expectation value of the number of matches per 1000 base pairs of random DNA sequence for each individual matrix, ranged from 0.03--0.35 for the EGRF elements. ETS1, ETS2, ELK1 and NRF2 were the components of the ETSF element, with re-values of \<0.01--2.05. The free version of the software does not detail the exact sequences of the modules, as it is their relative location, rather than sequence, that determines a module's functional activity.

The EGRF/ETSF module identifies novel proliferation-associated genes
--------------------------------------------------------------------

The known promoters of the human genome were screened for the EGRF/ETSF module using *Model Inspector*, based not on sequence alignment, but detection of individual elements and their position relative to each other. At the time of the experiment, the database contained 46,119 promoters with known transcripts. A total of 102 matches for the selected proliferation-associated module were detected in 30 genes ([Table 2](#t2-tog-2-2007-001){ref-type="table"}). All matches contained a model score of ≥85% specificity. The chromosomal locations of these genes were widely dispersed throughout the genome, excluding the possibility of co-regulation due to overlapping sequences (data not shown).

The products of the 30 genes were entered into *Bibliosphere* ([@b3-tog-2-2007-001]) to determine their functional context based on the scientific literature e.g. published experimental evidence of a role in affecting cellular proliferation ([Table 2](#t2-tog-2-2007-001){ref-type="table"}). Eleven of these genes (37%) have been implicated in cell proliferation in the literature, including KCNH2 and MCM7 ([@b15-tog-2-2007-001]; [@b32-tog-2-2007-001]) ([Table 2](#t2-tog-2-2007-001){ref-type="table"}). Six of the genes have been described in the literature as expressed in colonic neoplasia based on experimental data, and nine are up-regulated in colon cancer gene expression profiles in public databases ([Table 2](#t2-tog-2-2007-001){ref-type="table"}) ([@b5-tog-2-2007-001]). As a control functional context, a common disease process, inflammation, was explored in the 30 identified genes using *Bibliosphere*; only one (TLX2) has been associated with inflammation (data not shown).

Suppression of TSPAN3 and APLP2 inhibits cell proliferation in colorectal cell lines
------------------------------------------------------------------------------------

The experiments above identified genes containing a promoter module that is frequently present in genes associated with cell proliferation in colon cancer. In order to determine the functional significance of the presence of this module in these genes, the role of their knock-down by siRNA on cell proliferation was determined. We screened the identified genes using *Bibliosphere* for 1) reports of expression in colon cancer, 2) reports of a role in cell proliferation ([Table 2](#t2-tog-2-2007-001){ref-type="table"}). As our interest was in novel proliferation-associated genes which may be relevant to colon cancer, we selected three genes not previously reported as altered in colon cancer; TSPAN3, NDN and APLP2. They have been described as having positive, negative and unknown roles in cell proliferation ([@b27-tog-2-2007-001]; [@b28-tog-2-2007-001]). The TSPAN3 gene contains the EGRF/ETSF module at position 491-418 on the negative strand at 15q24.3. The APLP2 gene contained the EGRF/ETSF module at position 2492--2532 on the positive strand at 11q24. The NDN gene contained the EGRF/ETSF module at position 1268-1179 on the negative strand at 15q11.2-q12.

Gene expression of each gene in colon cancer was first measured from 3 diverse microarray databases; one from 36 types of normal tissue, one from 174 epithelial tumors that included 10 colorectal adenocarcinomas, and a third from primary and metastatic colorectal cell lines ([@b10-tog-2-2007-001]; [@b19-tog-2-2007-001]; [@b26-tog-2-2007-001]). Both TSPAN3 and APLP2 were expressed in normal colon, and colon cancer cell lines, although only TSPAN3 was relatively over-expressed in colonic adenocarcinoma tissue relative to other tumours ([Figure 3](#f3-tog-2-2007-001){ref-type="fig"}). NDN was not expressed in normal colon, adenocarcinoma or colon cancer cell lines.

Cells were transfected with siRNA designed to provide at least 70% silencing of expression, and mRNA levels and cell proliferation quantified ([@b21-tog-2-2007-001]). TSPAN3 expression in T84 colon cancer cell line was confirmed by RT-PCR ([Fig. 4a](#f4-tog-2-2007-001){ref-type="fig"}). siRNA caused a 62% inhibition of TSPAN3 expression at 24 hours ([Fig. 4a](#f4-tog-2-2007-001){ref-type="fig"}, p \< 0.05). Confirmation of cellular uptake was observed using the labeled fluorescent siRNA ([Fig. 4b](#f4-tog-2-2007-001){ref-type="fig"}). This led to a 40% reduction in cellular proliferation at 48 hours in T84 cells ([Fig. 4c](#f4-tog-2-2007-001){ref-type="fig"}, p \< 0.05). Neither scrambled siRNA or transfection agent alone affected cell proliferation. APLP2 expression in colon cancer cells was confirmed by RT-PCR ([Fig. 5a](#f5-tog-2-2007-001){ref-type="fig"}). siRNA caused a 45% inhibition of APLP2 expression at 24 hours ([Fig. 5a](#f5-tog-2-2007-001){ref-type="fig"}, p \< 0.05). Confirmation of cellular uptake was observed using the labeled fluorescent siRNA ([Fig. 5b](#f5-tog-2-2007-001){ref-type="fig"}). This inhibition led to a 40% reduction in cellular proliferation at 48 hours in CaCo2 cells ([Fig. 5c](#f5-tog-2-2007-001){ref-type="fig"}, p \< 0.05). Neither scrambled siRNA or transfection agent alone affected cell proliferation.

Discussion
==========

This study has demonstrated the use of promoter modules as bioinformatic "bait" to delineate key regulatory networks in colon cancer, and to identify novel biological players in cell proliferation. It is based on the premise that genes expressed in similar disease states share a common "footprint" of transcriptional regulatory processes for specific functional activities. The relative order and spacing of these transcription factor (TF) binding sites (TFBSs) within a module are often highly conserved through evolution, highlighting their importance in regulation. This conservation allows us to use computational searching to pinpoint these clusters of known TF binding sites rather than specific nucleotide sequences ([@b2-tog-2-2007-001]). Although the shared process selected for this study, proliferation, is not unique to cancer cells, it is a dominant process that partially defines this disease state. The presence of the EGRF/ETSF module in the promoter region of genes associated with cell proliferation suggests a role for this module in the regulation of cellular proliferative activity ([@b14-tog-2-2007-001]). Although this influence could be positive or negative, its frequency in the promoter regions of over-expressed genes in colon cancer cDNA libraries, compared to random promoter sets, suggests a pro-proliferative effect in this setting. The experimental data clearly suggests a role for the studied genes in cell proliferation, although whether this is actually dependent on the identified promoter module, would require further studies.

This strategy predicted a role for TSPAN3 in cell proliferation in colorectal cancer that has not previously been described. TSPAN3 is a member of the tetraspanin family of cell surface receptors that have been implicated in the cell proliferation process in oligodendrocytes ([@b28-tog-2-2007-001]). Our data demonstrating its expression in normal and neoplastic colon, and the negative effects of its inhibition on cell proliferation in colon cancer cell lines, confirming the predicted role based on promoter analysis. Further work will be required to determine whether this effect is unique to colon cancer cells, and which component of proliferation is involved. APLP2 is an amyloid-like protein precursor that plays a role in G-coupled signaling. It may be required for epithelial cell growth in wounds ([@b25-tog-2-2007-001]). This study suggests a role for APLP2 in colon cancer cell proliferation, which may be due to its key function in genomic segregation ([@b30-tog-2-2007-001]).

Although this study validates this approach in identifying co-regulated genes, the activation of the promoters involved has not been experimentally tested. As this work focuses on functionally relevant associations between genes and disease, we sought to examine the functional end-point primarily. The confirmation of alterations in expression and proliferation validates the computational predictions. We have not focused on the descriptive aspects of the module discussed e.g. sequence, as it is the strategic organization of the EGRF/ETSF matrix in the promoters of interest, rather than sequence composition, that confers its functional properties ([@b7-tog-2-2007-001]). Our intention was proof-of-concept evidence that could validate this bioinformatic approach.

In conclusion, this study demonstrates that an integrated *in silico* promoter analysis approach can be used to delineate novel cancer-associated genes. We have described a previously unreported role for TSPAN3 and APLP2, in cell proliferation in colon cancer based on a common promoter module. Further study of this module may provide increased understanding of this regulatory network.
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Supplementary 1
===============

  **Accession**   **Cluster**   **Name**                                                                           **Expression**   **Fold Diff**
  --------------- ------------- ---------------------------------------------------------------------------------- ---------------- ---------------
  NM_001644.2     560           apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 (APOBEC1)            Exclusive        54
  NM_001804.1     1545          caudal type homeo box transcription factor 1 (CDX1)                                Exclusive        14
  NM_005814       143131        glycoprotein A33 (transmembrane) (GPA33)                                           Exclusive        11
  NM_001986.1     77711         ets variant gene 4 (E1A enhancer binding protein, E1AF) (ETV4)                     Significant      20
  NM_001265.2     77399         caudal type homeo box transcription factor 2 (CDX2)                                Significant      20
  NM_138768.1     116051        myeloma overexpressed gene positive multiple myelomas) (MYEOV)                     Significant      14
  NM_004963.1     1085          guanylate cyclase 2C (heat stable enterotoxin receptor) (GUCY2C)                   Significant      13
  NM_024017.3     86327         homeo box B9 (HOXB9)                                                               Significant      6
  XM_032721.3     109358        ATPase, Class V, type 10B (ATP10B)                                                 Significant      5
  NM_033266.1     114905        ER to nucleus signalling 2 (ERN2)                                                  Significant      4
  NM_019010.1     84905         cytokeratin 20 (KRT20)                                                             Significant      4
  NM_005310.1     86859         growth factor receptor-bound protein 7 (GRB7)                                      Significant      4
  NM_001738.1     23118         carbonic anhydrase I (CA1)                                                         Significant      4
  NM_004306.1     181107        annexin A13 (ANXA13)                                                               Significant      3
  NM_007028.2     91096         tripartite motif-containing 31 (TRIM31)                                            Significant      
  NM_001500.1     1054435       GDP-mannose 4,6-dehydratase (GMDS)                                                 Preferential     39
  NM_005628.1     183556        solute carrier family 1 (neutral amino acid transporter), member 5 (SLC1A5)        Preferential     36
  NM_002276.2     182265        keratin 19 (KRT19)                                                                 Preferential     33
  NM_001569.2     182018        interleukin-1 receptor-associated kinase 1 (IRAK1)                                 Preferential     23
  NM_002295       356261        laminin receptor 1 (67kD, ribosomal protein SA) (LAMR1)                            Preferential     19
  NM_001402       493552        eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)                        Preferential     19
  NM_002087       180577        granulin (GRN)                                                                     Preferential     19
  NM_006597       180414        heat shock 70kD protein 8 (HSPA8)                                                  Preferential     18
  NM_005507       170622        cofilin 1 (non-muscle) (CFL1)                                                      Preferential     17
  NM_001903       254321        catenin (cadherin-associated protein), alpha 1 (102kD) (CTNNA1)                    Preferential     17
  NM_002819       172550        polypyrimidine tract binding protein 1 (PTBP1)                                     Preferential     17
  NM_007363       355861        non-POU domain containing, octamer-binding (NONO)                                  Preferential     17
  NM_002568                     poly(A) binding protein, cytoplasmic 1 (PABPC1)                                    Preferential     16
  NM_006516       169902        solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1)       Preferential     16
  NM_002046                     glyceraldehyde-3-phosphate dehydrogenase (GAPD)                                    Preferential     16
  NM_003906       389037        MCM3 minichromosome maintenance deficient 3 protein (MCM3AP)                       Preferential     15
  NM_004433       67928         E74-like factor 3 (ets domain transcription factor, epithelial-specific ) (ELF3)   Preferential     14
  NM_007127       166068        villin 1 (VIL1)                                                                    Preferential     14
  NM_000218       367809        potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1)              Preferential     13
  NM_003379       403997        villin 2 (ezrin) (VIL2)                                                            Preferential     13
  NM_001084       153357        procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3)                         Preferential     12
  NM_005789       152978        proteasome (prosome, macropain) activator subunit 3 (PSME3)                        Preferential     12
  NM_005561       150101        lysosomal-associated membrane protein 1 (LAMP1)                                    Preferential     11
  NM_005080       437638        X-box binding protein 1 (XBP1)                                                     Preferential     11
  NM_002105                     H2A histone family, member X (H2AFX)                                               Preferential     11
  NM_004429       144700        ephrin-B1 (EFNB1)                                                                  Preferential     10
  NM_014498                     golgi phosphoprotein 4 (GOLPH4)                                                    Preferential     9
                  139800        high-mobility group (nonhistone chromosomal) protein isoforms (HMGIY)              Preferential     9
  NM_007052       132370        NADPH oxidase 1 (NOX1)                                                             Preferential     9
  NM_001416       129673        eukaryotic translation initiation factor 4A, isoform 1(EIF4A1)                     Preferential     9
  NM_004655       127337        axin 2 (conductin, axil) (AXIN2)                                                   Preferential     9
  NM_004442       125124        EphB2 (EPHB2)                                                                      Preferential     9
  NM_000967       119598        ribosomal protein L3 (RPL3)                                                        Preferential     8
  NM_005063       119597        stearoyl-CoA desaturase (delta-9-desaturase) (SCD)                                 Preferential     8
  NM_000090       443625        collagen, type III, alpha 1 (COL3A1)                                               Preferential     8
  NM_012423       419535        ribosomal protein L13a (RPL13A)                                                    Preferential     8
                                                                                                                   Preferential     
  NM_006026       75307         H1 histone family, member X (H1FX)                                                 Preferential     8
  NM_001923       290758        damage-specific DNA binding protein 1 (127kD) (DDB1)                               Preferential     8
  NM_032044       105484        regenerating gene type IV (REG-IV)                                                 Preferential     8
  NM_003258       105097        thymidine kinase 1, soluble (TK1)                                                  Preferential     7
  XM_039877       102482        mucin 5, subtype B, tracheobronchial (MUC5B)                                       Preferential     7
  NM_005724       100090        tetraspan 3 (TSPAN-3)                                                              Preferential     7
  NM_000972       416801        ribosomal protein L7a (RPL7A)                                                      Preferential     7
  NM_018952       98428         homeo box B6 (HOXB6)                                                               Preferential     7
  NM_015925       312129        Similar to liver-specific bHLH-Zip transcription factor                            Preferential     7
  NM_000075       95577         cyclin-dependent kinase 4 (CDK4)                                                   Preferential     6
  NM_006408       226391        anterior gradient 2 homolog (Xenepus laevis) (AGR2)                                Preferential     6
  NM_004044       90280         5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ATIC)             Preferential     6
  NM_004494       89525         hepatoma-derived growth factor (high-mobility group protein 1-like) (HDGF)         Preferential     6
  NM_004063       89436         cadherin 17, LI cadherin (liver-intestine) (CDH17)                                 Preferential     6
  NM_000213       85266         integrin, beta 4 (ITGB4)                                                           Preferential     6
  NM_001730       84728         Kruppel-like factor 5 (intestinal) (KLF5)                                          Preferential     6
  NM_001255       82906         CDC20 cell division cycle 20 homolog (S. cerevisiae) (CDC20)                       Preferential     5
  NM_001747       82422         capping protein (actin filament), gelsolin-like (CAPG)                             Preferential     5
  NM_002534       442936        2′,5′-oligoadenylate synthetase 1 (40--46 kD) (OAS1)                               Preferential     5
  NM_000178       82327         glutathione synthetase (GSS)                                                       Preferential     5
  NM_000903       406515        NAD(P)H dehydrogenase, quinone 1 (NQO1)                                            Preferential     5
  NM_002394       79748         solute carrier family 3 member 2 (SLC3A2)                                          Preferential     5
  NM_005567       79339         lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP)                 Preferential     5
  NM_000404                     galactosidase, beta 1 (GLB1)                                                       Preferential     5
  NM_006907       458332        pyrroline-5-carboxylate reductase 1 (PYCR1)                                        Preferential     5
  NM_000291       78771         phosphoglycerate kinase 1 (PGK1)                                                   Preferential     5
  NM_002635       290404        solute carrier family 25 member 3 (SLC25A3)                                        Preferential     5
  NM_001640       221589        N-acylaminoacyl-peptide hydrolase (APEH)                                           Preferential     5
  NM_005030       329989        polo-like kinase (Drosophila) (PLK)                                                Preferential     5
  NM_002224       77515         inositol 1,4,5-triphosphate receptor, type 3 (ITPR3)                               Preferential     4
  NM_002668       77422         proteolipid protein 2 (colonic epithelium-enriched) (PLP2)                         Preferential     4
  NM_016343       77204         centromere protein F (350/400kD, mitosin) (CENPF)                                  Preferential     4
  NM_005916       438720        MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) (MCM7)                 Preferential     4
  NM_001006       356572        ribosomal protein S3A (RPS3A)                                                      Preferential     4
  NM_000701       371889        ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1)                          Preferential     4
  NM_000990       356542        ribosomal protein L27a (RPL27A)                                                    Preferential     4
  NM_015379       410497        brain protein I3 (BRI3)                                                            Preferential     4
  NM_012408       191990        protein kinase C binding protein 1 (PRKCBP1)                                       Preferential     4
  NM_002773       75799         protease, serine, 8 (prostasin) (PRSS8)                                            Preferential     4
  NM_002951       406532        ribophorin II (RPN2)                                                               Preferential     4
  NM_001673       446546        asparagine synthetase (ASNS)                                                       Preferential     4
  NM_002862       145820        phosphorylase, glycogen; brain (PYGB)                                              Preferential     4
  NM_000918       410578        procollagen-proline, 2-oxoglutarate 4-dioxygenase (P4HB)                           Preferential     3
  NM_000228       436983        laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD) (LAMB3)            Preferential     3
  NM_001034       226390        ribonucleotide reductase M2 polypeptide (RRM2)                                     Preferential     3
  NM_003217       35052         testis enhanced gene transcript (BAX inhibitor 1) (TEGT)                           Preferential     3
  NM_001658       286221        ADP-ribosylation factor 1 (ARF1)                                                   Preferential     3
  NM_000014                     alpha-2-macroglobulin (A2M)                                                        Preferential     3
  NM_007355       74335         heat shock 90kD protein 1, beta (HSPCB)                                            Preferential     3
  NM_001288       414565        chloride intracellular channel 1 (CLIC1)                                           Preferential     3
                                                                                                                   Preferential     
  NM_007367       74111         RNA binding protein (RALY)                                                         Preferential     3
  NM_002483       436718        carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)                Preferential     3
  NM_021220       386387        zinc finger protein 339 (ZNF339)                                                   Preferential     3
  NM_001202       68879         bone morphogenetic protein 4 (BMP4)                                                Preferential     3
  NM_000224       406013        keratin 18 (KRT18)                                                                 Preferential     3
  NM_019894       414005        transmembrane protease, serine 4 (TMPRSS4)                                         Preferential     3
  NM_002032       448738        ferritin, heavy polypeptide 1 (FTH1)                                               Preferential     3
  NM_016276       62863         serum/glucocorticoid regulated kinase 2 (SGK2)                                     Preferential     3
  NM_003756       127149        eukaryotic translation initiation factor 3, subunit 3 (gamma, 40kD) (EIF3S3)       Preferential     3
  NM_003751       371001        eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD) (EIF3S9)        Preferential     3
  NM_004526       57101         MCM2 minichromosome maintenance deficient 2, (S. cerevisiae) (MCM2)                Preferential     3
  NM_021978       56937         suppression of tumorigenicity 14 (colon carcinoma, epithin) (ST14)                 Preferential     3
  NM_006187       129895        2′-5′-oligoadenylate synthetase 3 (100 kD) (OAS3)                                  Preferential     3
  NM_003753       55682         eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD) (EIF3S7)     Preferential     3
  NM_001712       512682        carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)                Preferential     3
  NM_005727                     tetraspan 1 (TSPAN-1)                                                              Preferential     3
  NM_021102       31439         serine protease inhibitor, Kunitz type, 2 (SPINT2)                                 Preferential     3
  NM_007183       26557         plakophilin 3 (PKP3)                                                               Preferential     3
  NM_001306       25640         claudin 3 (CLDN3)                                                                  Preferential     3
  NM_004572       25051         plakophilin 2 (PKP2)                                                               Preferential     3
  NM_004289       404741        nuclear factor (erythroid-derived 2)-like 3 (NFE2L3)                               Preferential     3
  NM_003627       444159        SLC43A1                                                                            Preferential     2
  NM_005498       18894         adaptor-related protein complex 1, mu 2 subunit (AP1M2)                            Preferential     2
  NM_005558       18141         ladinin 1 (LAD1)                                                                   Preferential     2
  NM_002707       17883         protein phosphatase 1G magnesium-dependent, gamma isoform (PPM1G)                  Preferential     2
  NM_020384       16098         claudin 2 (CLDN2)                                                                  Preferential     2
  NM_001614       14376         actin, gamma 1 (ACTG1)                                                             Preferential     2
  NM_052854       405961        old astrocyte specifically induced substance (OASIS)                               Preferential     2
  NM_016234       11638         fatty-acid-Coenzyme A ligase, long-chain 5 (FACL5)                                 Preferential     2
  NM_021107       411125        mitochondrial ribosomal protein S12 (MRPS12)                                       Preferential     2
  NM_002335       6347          low density lipoprotein receptor-related protein 5 (LRP5)                          Preferential     2
  NM_022085       430169        thioredoxin related protein (MGC3178)                                              Preferential     2
  NM_033049       5940          mucin 13, epithelial transmembrane (MUC13)                                         Preferential     2
  NM_014865                     chromosome condensation-related SMC-associated protein 1 (CNAP1)                   Preferential     2
  NM_006098       5662          guanine nucleotide binding protein beta polypeptide 2-like 1 (GNB2L1)              Preferential     2
  NM_024526       5366          epidermal growth factor receptor pathway related protein 3 (EPS8R3)                Preferential     1
  NM_006149       5302          lectin, galactoside-binding, soluble, 4 (galectin 4) (LGALS4)                      Preferential     1
  NM_014275       437277        mannosyl (alpha-1,3-) (MGAT4B)                                                     Preferential     1
  NM_003752       388163        eukaryotic translation initiation factor 3, subunit 8 (110kD) (EIF3S8)             Preferential     
                  3989          plexin B2 (PLXNB2)                                                                 Preferential     
  NM_002447       2942          macrophage stimulating 1 receptor (c-met-related tyrosine kinase) (MST1R)          Preferential     
  NM_001038                     sodium channel, nonvoltage-gated 1 alpha (SCNN1A)                                  Preferential     
  NM_002083       2704          glutathione peroxidase 2 (gastrointestinal) (GPX2)                                 Preferential     
  NM_005186       356181        calpain 1, (mu/I) large subunit (CAPN1)                                            Preferential     
  NM_001404       256184        eukaryotic translation elongation factor 1 gamma (EEF1G)                           Preferential     
  NM_003334       406683        ubiquitin-activating enzyme E1 (UBE1)                                              Preferential     
  NM_005998       1708          chaperonin containing TCP1, subunit 3 (gamma) (CCT3)                               Preferential     
  NM_012073       1600          chaperonin containing TCP1, subunit 5 (epsilon) (CCT5)                             Preferential     
  NM_000077       421349        cyclin-dependent kinase inhibitor 2A (melanoma (CDKN2A)                            Preferential     
  NM_002014       848           FK506 binding protein 4 (59kD) (FKBP4)                                             Preferential     
  NM_004502       436181        homeo box B7 (HOXB7)                                                               Preferential     
  NM_004966       808           heterogeneous nuclear ribonucleoprotein F (HNRPF)                                  Preferential     
  NM_002354       692           tumor-associated calcium signal transducer 1 (TACSTD1)                             Preferential     
  NM_005435       334           Rho guanine nucleotide exchange factor (GEF) 5 (ARHGEF5)                           Preferential     
  NM_002457       458274        mucin 2, intestinal/tracheal (MUC2)                                                Preferential     
  NM_000968       186350        ribosomal protein L4 (RPL4)                                                        Preferential     

![**Summary of bioinformatics methods used.** References for each method contained in text.](tog-2-2007-001f1){#f1-tog-2-2007-001}

![**EGRF/ETSF module is common to proliferation genes expressed in colon cancer.** EGRF element (purple), ETSF element (yellow) and combined module (grey) location in promoter region of representative sample of input loci relative to transcription start site (TSS, red arrow). Graphical output generated by *FrameWorker* software.](tog-2-2007-001f2){#f2-tog-2-2007-001}

![**TSPAN3 and APLP2 are expressed in normal and neoplastic colon**. Expression of TSPAN3, APLP2 and NDN in microarray profiles of: (**a**) normal colon (Log2 of user-provided count of gene expression on oligonucleotide microarray (Affymetrix U133) using pooled RNA) (**b**) primary colon cancer cell line (black bars) and metastatic colon cancer cell line (grey bars) (Log2 of user-provided count of gene expression on oligonucleotide microarray (Affymetrix U133) using pooled RNA) (**c**) 174 human epithelial tumors (Co; colon samples, *red*, increased gene expression; *green*, decreased expression; *black*, median level of gene expression. The color intensity is proportional to the hybridization intensity of a gene from its median level across all samples.](tog-2-2007-001f3){#f3-tog-2-2007-001}

![**Inhibition of TSPAN3 expression by siRNA inhibits colon cell line proliferation.** (**a**) RNA extracted from transfected and untransfected T84 cells after 24 hours was reverse transcribed to cDNA and probed for TSPAN3 using Taqman PCR (expressed in arbitrary units normalised to 18s RNA). (**b**) T84 cells in a 96-well plate were transfected with a control fluorescent-labeled siRNA to confirm transfection efficiency. (**c**) Proliferation of transfected T84 cells in a 96-well plate was assessed after 24 hours using the MTS Cell Proliferation Assay. Control = media only, vehicle = media and transfection agent (Lipofectamine), scrambled siRNA = transfection agent and scrambled siRNA, and TSPAN3 siRNA = custom-designed TSPAN3 siRNA (10 nm)](tog-2-2007-001f4){#f4-tog-2-2007-001}

![**Inhibition of APLP2 expression by siRNA inhibits colon cell line proliferation.** (**a**) RNA extracted from transfected and untransfected T84 cells after 24 hours was reverse transcribed to cDNA and probed for APLP2 using Taqman PCR (expressed in arbitrary units normalised to 18s RNA) (**b**) T84 cells in a 96-well plate were transfected with a control fluorescent-labeled siRNA to confirm transfection efficiency (**c**) Proliferation of transfected T84 cells in a 96-well plate was assessed after 24 hours using the MTS Cell Proliferation Assay. Control = media only, vehicle = media and transfection agent (Lipofectamine), scrambled siRNA = transfection agent and scrambled siRNA, and APLP2 siRNA = custom-designed APLP2 siRNA (10 nm)](tog-2-2007-001f5){#f5-tog-2-2007-001}

###### 

Genes associated with cell proliferation in colon cancer that had promoter regions identified (verified = published experimental verification, predicted = transcript with 5' end confirmed by *Gene2Promoter 2004*).

  **mRNA**     **Locus**           **Transcript/TSS**   **Quality Level**
  ------------ ------------------- -------------------- -------------------
  NM_002394    SLC3A2 (Loc 6520)   AK090758_1           Verified
  AK094620_1   Verified                                 
  NM_002394    Predicted                                
  NM_005916    MCM7                AK055379_1           Verified
  AK096959_1   Verified                                 
  NM_005916    Predicted                                
  NM_014865    CNAP1               AK022511_1           Verified
  AK125155_1   Verified                                 
  AK128354_1   Verified                                 
  NM_001034    RRM2                AK092671_1           Verified
  AK123010_1   Verified                                 
  NM_001034    Predicted                                
  NM_002707    PPM1G               AK127593_1           Verified
  NM_002707    Predicted                                
  NM_177983    Predicted                                
  NM_000077    CDKN2A              NM_058195            Predicted
  NM_016343    CENPF               NM_016343            Predicted
  NM_002447    MST1R               NM_002447            Predicted
  NM_001255    CDC20               NM_001255            Predicted
  NM_004526    MCM2                AK128291_1           Verified
  NM_005186    CAPN1               AK025380_1           Verified
  AK097277_1   Verified                                 
  NM_005186    Predicted                                
  NM_004494    HDGF                AK096411_1           Verified
  NM_004494    Predicted                                
  NM_003334    UBE1                AK097343_1           Verified
  NM_003334    Predicted                                
  NM_002335    LRP5                NM_002335            Predicted
  NM_002032    FTH1                NM_002032            Predicted
  NM_005030    PLK                 NM_005030            Predicted

###### 

Identified genes that contain the EGRF/ETSF promoter module in their promoter regions.

  **Accession**   **Gene[^a^](#tfn1-tog-2-2007-001){ref-type="table-fn"}**   **Model score**   **Effect on proliferation[^b^](#tfn2-tog-2-2007-001){ref-type="table-fn"}**   **Expression in colon cancer[^c^](#tfn3-tog-2-2007-001){ref-type="table-fn"}**   **Public microarray data[^d^](#tfn4-tog-2-2007-001){ref-type="table-fn"}**   **References**
  --------------- ---------------------------------------------------------- ----------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  AB000381        GML                                                        89%               negative                                                                      Yes - in cell lines                                                              No                                                                           Oncogene 1996; 13 (9) 1965--7. Int J Clin Oncol. 2001 Apr; 6(2):90--6
  AB001517        TMEM1                                                      90%               ?                                                                             ?                                                                                No                                                                           
  AB001523        PWP2                                                       90%               ?                                                                             ?                                                                                No                                                                           
  AB003173        WRN                                                        90%               positive                                                                      Yes -- in unmethylated tumours                                                   Yes                                                                          DNA Repair 2004; 3(5): 475--482 Proc Natl Acad Sci USA. 2006 Jun 6; 103(23):8822--7
  AB003469        MCM5                                                       90%               ?                                                                             Yes                                                                              Yes                                                                          Clin Cancer Res. 1999 Aug; 5(8):2121--32
  AB004270        MCM7                                                       90%               positive                                                                      ?                                                                                Yes                                                                          Oncogene 2006; 25(7): 1090--9
  AB005647        NPR2                                                       90%               ?                                                                             ?                                                                                No                                                                           
  AB006075        HMG-CoA synthase                                           89%               ?                                                                             Yes                                                                              No                                                                           Mol Carcinog. 2001 Nov; 32(3):154--66.
  AB006684        AIRE                                                       91%               ?                                                                             ?                                                                                No                                                                           
  AB007828        NDN                                                        88%               negative                                                                      ?                                                                                No                                                                           Gene 1998; 213(1--2): 65--72
  AB008496        COL4A3                                                     90%               negative                                                                      ?                                                                                No                                                                           J Biol Chem 2000; 275 (28):21340--8
  AB008502        TLX2                                                       90%               ?                                                                             ?                                                                                No                                                                           
  AB008681        ACVR2B                                                     92%               positive                                                                      Yes -- in cell lines                                                             No                                                                           Dev Biol 2004; 266(2): 334--45 Gut. 2001 Sep; 49(3):409--17
  AB008822        TNFRSF1 1B                                                 92%               negative                                                                      ?                                                                                No                                                                           J Clin Invest 2001; 107(10):1235--4
  AB009071        KCNH2                                                      88%               positive                                                                      Yes                                                                              Yes                                                                          J Biol Chem 2003; 278(5):2947--55 Cancer Res. 2004 Jan 15; 64(2):606--11
  AB009667        Klotho                                                     95%               ?                                                                             ?                                                                                No                                                                           
  AB009777        NID2                                                       85%               ?                                                                             ?                                                                                No                                                                           
  AB012286        ITGB4                                                      90&               positive                                                                      ?                                                                                Yes                                                                          Cancer Res 2005; 65(23):10674--9
  AB012668        hFUCT-7                                                    91%               ?                                                                             ?                                                                                No                                                                           
  AB015751        APLP2                                                      96%               ?                                                                             ?                                                                                No                                                                           
  AB016243        SLC9A3R2                                                   91%               ?                                                                             ?                                                                                No                                                                           
  AB016656        LIMK2b                                                     91%               ?                                                                             ?                                                                                No                                                                           
  AB016767        TERT                                                       95%               ?                                                                             ?                                                                                No                                                                           
  AB017018        HNRPDL                                                     94%               ?                                                                             ?                                                                                Yes                                                                          
  AB017547        SPR                                                        93%               ?                                                                             ?                                                                                Yes                                                                          
  AB017567        LIPT1                                                      95%               ?                                                                             ?                                                                                No                                                                           
  AB017602        PDE9A                                                      90%               ?                                                                             ?                                                                                Yes                                                                          
  AB018192        PHC1                                                       95%               ?                                                                             ?                                                                                No                                                                           
  AB018401        DHH                                                        90%               positive                                                                      ?                                                                                No                                                                           Development 2004 Oct; 131(20):5009--19
  AK001326        TSPAN3                                                     90%               positive                                                                      ?                                                                                Yes                                                                          *J Cell Biol* 153:295--305

HUGO accepted gene name

Published experimental evidence of effect on cell proliferation

Experimental evidence of increased protein or mRNA expression in colon cancer

Upregulation of gene in public microarray database of expression relative to normal ([@b5-tog-2-2007-001])
